Active	Status	Sponsor type	Region	Phase	Filter
10 Active 5 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lukin, Dana
VERDICT, NCT04259138: Determination of the Optimal Treatment Target in Ulcerative Colitis	Active, not recruiting	4	672	Europe, Canada, US, RoW	Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C	Alimentiv Inc., Takeda Development Center Americas, Inc.	Colitis, Ulcerative	03/26	03/26
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)	Recruiting	4	65	Canada, US	Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550	Takeda	Ulcerative Colitis	07/27	07/27
PL8177-205, NCT05466890: Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC)	Recruiting	2	28	US	PL8177 Placebo, Placebo, PL8177, Active study medication	Palatin Technologies, Inc	Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare	04/24	08/24
NCT06109441: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics	Recruiting	2	30	Canada, US	ALTB-268	AltruBio Inc.	Ulcerative Colitis	04/25	03/26
NCT03952364: The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States	Recruiting	N/A	200	US	PredictSURE IBD™	PredictImmune Ltd, The Crohn's and Colitis Foundation	Crohn Disease, Ulcerative Colitis, IBD, Inflammatory Bowel Diseases	06/22	06/22
Abd, Mortadha
No trials found